SEC Filing Summary
Filing identity: The supplied filing is Inotek Pharmaceuticals Corporation’s unaudited Form 10-Q for the quarter ended June 30, 2017. It does not identify Rocket Pharmaceuticals, Inc.; verify that this is the intended filing.
Business Context and Reporting Period
Inotek was a clinical-stage biopharmaceutical company focused on ocular diseases, especially glaucoma. It had no approved products and no product revenue. The report covers the three and six months ended June 30, 2017, compared with the same periods in 2016. Amounts below are in U.S. dollars; financial statement amounts are in thousands unless otherwise stated.
After quarter-end, on July 7, 2017, Inotek announced that its Phase 2 fixed-dose combination trial of trabodenoson and latanoprost missed its primary endpoint. In July, the company voluntarily discontinued trabodenoson development and began pursuing strategic alternatives with Perella Weinberg Partners.
Financial Performance and Position
| Metric | Q2 2017 | Q2 2016 | Six months 2017 | Six months 2016 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $3.624 million | $6.465 million | $10.721 million | $14.080 million |
| General and administrative expense | $2.232 million | $2.315 million | $5.101 million | $4.837 million |
| Operating loss | $5.856 million | $8.780 million | $15.822 million | $18.917 million |
| Net loss | $6.562 million | $8.684 million | $17.232 million | $18.752 million |
| Basic and diluted loss per share | $0.24 | $0.33 | $0.64 | $0.71 |
Gross margin is not applicable because the company reported no product revenue. Q2 operating expenses were lower year over year, mainly reflecting reduced Phase 3 trial and preclinical costs; the six-month G&A increase primarily reflected higher stock-based compensation. Net loss improved year over year despite new interest expense on the 2021 notes.
- Liquidity at June 30, 2017: Cash and cash equivalents of $27.610 million and short-term investments of $81.144 million, totaling $108.754 million. Total current assets were $109.821 million; current liabilities were $4.016 million.
- Cash flow, six months: Operating cash use was $17.539 million, versus $16.996 million in 2016. Investing activities provided $15.316 million, largely from investment maturities net of purchases; financing activities provided $0.035 million. Cash and cash equivalents declined $2.188 million to $27.610 million.
- Debt: $52.0 million principal amount of unsecured 5.75% convertible senior notes due August 2021; carrying value was $49.242 million after unamortized issuance costs. Effective interest rate was 7.3%. The company reported approximately $1.5 million of interest due each February 1 and August 1, with principal due at maturity.
- Equity and accumulated losses: Accumulated deficit was $256.109 million; stockholders’ equity was $57.530 million. Common shares outstanding were 27,010,202 at June 30, 2017.
Material Changes, Outlook, and Risks
- MATrX-1, the pivotal Phase 3 trabodenoson monotherapy trial, missed its primary endpoint in January 2017. The company cited a larger-than-expected placebo response; it also reported certain positive secondary endpoint findings and no significant safety or tolerability events.
- The Phase 2 combination trial results announced July 7 showed no meaningful clinical advantage over latanoprost alone at Day 56. Development of trabodenoson was subsequently discontinued, and research and development activities were suspended while the company evaluated strategic options.
- Management estimated existing cash and investments would fund operations into 2019, based on current assumptions. It expected R&D expense to decline in the second half of 2017 and said 2017 aggregate operating expenses, excluding strategic-transaction-specific costs, were not expected to exceed 2016. G&A could rise due to strategic review and litigation costs.
- No transaction was assured. The filing warns that a failed strategic review could lead the board to consider dissolution and liquidation; a transaction or other fundamental change could also trigger noteholder repurchase rights. Additional financing might be needed, and could dilute shareholders or require unfavorable terms.
- As a subsequent event, the company expected to write down trabodenoson clinical-supply equipment with a June 30 net book value of $437,000, with a charge expected in the quarter ending September 30, 2017. The amount of the eventual charge was not specified.
- A putative securities class action, amended July 10, alleges misleading statements and omissions relating to trabodenoson trials and seeks unspecified damages, interest, and fees. The company said it intended to defend itself.
- Other material risks include the company’s dependence on strategic alternatives after discontinuing its sole clinical-stage candidate, ongoing cash burn and debt service, possible NASDAQ delisting (the filing noted trading below the $1 minimum bid threshold during Q3), potential note repayment upon a fundamental change, and volatile share price.
Important Facts for Investors to Verify
- Confirm whether this Inotek 10-Q is the intended filing for the requested company, Rocket Pharmaceuticals, Inc.
- Check subsequent SEC filings and announcements for the outcome of the strategic review, any merger, sale, liquidation, or change in operating plans.
- Verify the actual cash runway against later spending, transaction costs, liabilities, and note interest and principal obligations.
- Review subsequent disclosures on the trabodenoson equipment impairment and any other restructuring or asset charges.
- Track the securities litigation, NASDAQ listing compliance, and whether any event triggered the convertible-note fundamental-change provisions.